238 related articles for article (PubMed ID: 3146370)
1. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.
Van de Werf F; Arnold AE
BMJ; 1988 Nov; 297(6660):1374-9. PubMed ID: 3146370
[TBL] [Abstract][Full Text] [Related]
2. Lessons from the European Cooperative recombinant tissue-type plasminogen activator (rt-PA) versus placebo trial.
Van de Werf F
J Am Coll Cardiol; 1988 Dec; 12(6 Suppl A):14A-19A. PubMed ID: 3142943
[TBL] [Abstract][Full Text] [Related]
3. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty.
Simoons ML; Arnold AE; Betriu A; de Bono DP; Col J; Dougherty FC; von Essen R; Lambertz H; Lubsen J; Meier B
Lancet; 1988 Jan; 1(8579):197-203. PubMed ID: 2893037
[TBL] [Abstract][Full Text] [Related]
4. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group.
Lancet; 1992 Mar; 339(8796):753-70. PubMed ID: 1347801
[TBL] [Abstract][Full Text] [Related]
5. Multicenter trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: effects on infarct size and left ventricular function.
Bassand JP; Machecourt J; Cassagnes J; Anguenot T; Lusson R; Borel E; Peycelon P; Wolf E; Ducellier D
J Am Coll Cardiol; 1989 Apr; 13(5):988-97. PubMed ID: 2647817
[TBL] [Abstract][Full Text] [Related]
6. Recombinant tissue-type plasminogen activator and immediate angioplasty in acute myocardial infarction. One-year follow-up. The European Cooperative Study Group.
Arnold AE; Simoons ML; Van de Werf F; de Bono DP; Lubsen J; Tijssen JG; Serruys PW; Verstraete M
Circulation; 1992 Jul; 86(1):111-20. PubMed ID: 1617763
[TBL] [Abstract][Full Text] [Related]
7. Significance of initial ST segment elevation and depression for the management of thrombolytic therapy in acute myocardial infarction. European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator.
Willems JL; Willems RJ; Willems GM; Arnold AE; Van de Werf F; Verstraete M
Circulation; 1990 Oct; 82(4):1147-58. PubMed ID: 2119263
[TBL] [Abstract][Full Text] [Related]
8. A double blind placebo controlled study of early and late administration of recombinant tissue plasminogen activator in acute myocardial infarction.
McNeill AJ; Cunningham SR; Flannery DJ; Dalzell GW; Wilson CM; Campbell NP; Khan MM; Patterson GC; Webb SW; Adgey AA
Br Heart J; 1989 Apr; 61(4):316-21. PubMed ID: 2496740
[TBL] [Abstract][Full Text] [Related]
9. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators.
Hsia J; Hamilton WP; Kleiman N; Roberts R; Chaitman BR; Ross AM
N Engl J Med; 1990 Nov; 323(21):1433-7. PubMed ID: 2122251
[TBL] [Abstract][Full Text] [Related]
10. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group.
Thompson PL; Aylward PE; Federman J; Giles RW; Harris PJ; Hodge RL; Nelson GI; Thomson A; Tonkin AM; Walsh WF
Circulation; 1991 May; 83(5):1534-42. PubMed ID: 1902404
[TBL] [Abstract][Full Text] [Related]
11. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
Johns JA; Gold HK; Leinbach RC; Yasuda T; Gimple LW; Werner W; Finkelstein D; Newell J; Ziskind AA; Collen D
Circulation; 1988 Sep; 78(3):546-56. PubMed ID: 3136953
[TBL] [Abstract][Full Text] [Related]
12. Emergency coronary artery bypass surgery preserves global and regional left ventricular function after intravenous tissue plasminogen activator therapy for acute myocardial infarction.
Kereiakes DJ; Topol EJ; George BS; Abbottsmith CW; Stack RS; Candela RJ; O'Neill WW; Martin LH; Califf RM
J Am Coll Cardiol; 1988 May; 11(5):899-907. PubMed ID: 2965716
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the effect of thrombolytic treatment on infarct size and left ventricular function by enzymatic, scintigraphic, and angiographic methods. The European Cooperative Study Group for Recombinant Tissue Type Plasminogen Activator.
Mortelmans L; Vanhaecke J; Lesaffre E; Arnold A; Urbain JL; Hermens W; De Roo M; De Geest H; Verstraete M; Van de Werf F
Am Heart J; 1990 Jun; 119(6):1231-7. PubMed ID: 2112877
[TBL] [Abstract][Full Text] [Related]
14. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.
Lancet; 1990 Jul; 336(8707):65-71. PubMed ID: 1975321
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial.
Ross AM; Coyne KS; Reiner JS; Greenhouse SW; Fink C; Frey A; Moreyra E; Traboulsi M; Racine N; Riba AL; Thompson MA; Rohrbeck S; Lundergan CF
J Am Coll Cardiol; 1999 Dec; 34(7):1954-62. PubMed ID: 10588209
[TBL] [Abstract][Full Text] [Related]
16. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
Cannon CP; McCabe CH; Henry TD; Schweiger MJ; Gibson RS; Mueller HS; Becker RC; Kleiman NS; Haugland JM; Anderson JL
J Am Coll Cardiol; 1994 Apr; 23(5):993-1003. PubMed ID: 8144799
[TBL] [Abstract][Full Text] [Related]
17. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
GUSTO Angiographic Investigators
N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430
[TBL] [Abstract][Full Text] [Related]
18. Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group.
Lancet; 1988 Jan; 1(8579):203-8. PubMed ID: 2893038
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of APSAC and rt-PA on infarct size and left ventricular function in acute myocardial infarction. A multicenter randomized study.
Bassand JP; Cassagnes J; Machecourt J; Lusson JR; Anguenot T; Wolf JE; Maublant J; Bertrand B; Schiele F
Circulation; 1991 Sep; 84(3):1107-17. PubMed ID: 1909218
[TBL] [Abstract][Full Text] [Related]
20. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial.
de Bono DP; Simoons ML; Tijssen J; Arnold AE; Betriu A; Burgersdijk C; López Bescos L; Mueller E; Pfisterer M; Van de Werf F
Br Heart J; 1992 Feb; 67(2):122-8. PubMed ID: 1540431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
